These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15526239)

  • 1. Aldosterone blockade in heart failure.
    Struthers AD
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S23-7. PubMed ID: 15526239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
    Pitt B; Zannad F; Remme WJ; Cody R; Castaigne A; Perez A; Palensky J; Wittes J
    N Engl J Med; 1999 Sep; 341(10):709-17. PubMed ID: 10471456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone inhibition reduces the risk of sudden cardiac death in patients with heart failure.
    Anand K; Mooss AN; Mohiuddin SM
    J Renin Angiotensin Aldosterone Syst; 2006 Mar; 7(1):15-9. PubMed ID: 17083069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure.
    Shah NC; Pringle S; Struthers A
    J Renin Angiotensin Aldosterone Syst; 2006 Mar; 7(1):20-30. PubMed ID: 17083070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure.
    Shah NC; Pringle SD; Donnan PT; Struthers AD
    J Hypertens; 2007 Nov; 25(11):2345-51. PubMed ID: 17921831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Arrhythmia risk stratification in patients with heart failure according to drug treatment and its effects].
    Gronda E; Mangiavacchi M; Andreuzzi B; Municinò A
    Ital Heart J Suppl; 2001 Dec; 2(12):1278-83. PubMed ID: 11838348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reassessing guidelines for heart failure.
    Drexler H; Wollert KC
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S28-33. PubMed ID: 15526240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Left-ventricular hypertrophy as a cardiac risk factor: role of the renin-angiotensin-aldosterone system].
    Erne P
    Praxis (Bern 1994); 1996 Feb; 85(8):227-33. PubMed ID: 8701189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design].
    Cacciatore G; Boccanelli A; Mureddu GF; Maggioni AP; Latini R; Masson S; de Simone G;
    Ital Heart J; 2005 May; 6 Suppl 1():66S-74S. PubMed ID: 15945301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone receptor antagonism in heart failure.
    Jennings DL; Kalus JS; O'Dell KM
    Pharmacotherapy; 2005 Aug; 25(8):1126-33. PubMed ID: 16207104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone antagonists in congestive heart failure.
    Soberman J; Chafin CC; Weber KT
    Curr Opin Investig Drugs; 2002 Jul; 3(7):1024-8. PubMed ID: 12186262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade.
    Pitt B; Fonarow GC; Gheorghiade M; Deedwania PC; Duprez DA
    Am J Cardiol; 2006 May; 97(10A):26F-33F. PubMed ID: 16698332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fiftieth anniversary of aldosterone: from discovery to cardiovascular therapy.
    Tan LB; Schlosshan D; Barker D
    Int J Cardiol; 2004 Sep; 96(3):321-33. PubMed ID: 15310530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular basis for therapeutic choices in heart failure.
    Opie LH
    Circulation; 2004 Oct; 110(17):2559-61. PubMed ID: 15505109
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.